{
  "run": {
    "id": "cmnr12zce02ryp658pt5qppnv",
    "region": "US",
    "assetId": "cmnr12zbw02rup658o6143ldc",
    "ticker": "CL",
    "snapshotId": "cmnr12zc602rwp658lwh0l230",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:20:09.324Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr12zc602rwp658lwh0l230",
      "assetId": "cmnr12zbw02rup658o6143ldc",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 85.55,
          "dayLow": 83.705,
          "volume": 4301437,
          "dayHigh": 85.61,
          "currency": "USD",
          "prevClose": 83.13,
          "week52Low": 74.55,
          "week52High": 99.33
        },
        "fundamentals": {
          "pe": 29.9318181818182,
          "beta": 0.236175153456024,
          "epsTTM": 2.64,
          "fcfTTM": 3330000000,
          "growth": {
            "epsYoy": -0.2521246458923512,
            "revenueYoy": 0.01397940400975076
          },
          "sector": "Perfumes, Cosmetics & Other Toilet Preparations",
          "margins": {
            "net": 0.1046020998920616,
            "gross": 0.6010695711902659,
            "operating": 0.162201942890786
          },
          "website": "https://colgatepalmolive.com",
          "industry": "Consumer goods",
          "pegRatio": -1.18718335035751,
          "ebitdaTTM": 3942000000,
          "forwardPe": 20.2615384615385,
          "marketCap": 73400000000,
          "totalCash": 1288000000,
          "totalDebt": 8954000000,
          "debtEquity": 165.814814814815,
          "quickRatio": 0.44797898730483,
          "revenueTTM": 20382000000,
          "companyName": "COLGATE PALMOLIVE CO",
          "priceToBook": 175.078010958904,
          "currentRatio": 0.8330658105939005,
          "dividendYield": 0.028527400560414,
          "returnOnAssets": 0.1305572565829761,
          "returnOnEquity": 39.4814814814815,
          "analystOpinions": null,
          "businessSummary": "The Colgate-Palmolive Company, commonly known as Colgate-Palmolive, is an American multinational consumer products company headquartered on Park Avenue in Midtown Manhattan, New York City. The company specializes in the production, distribution, and provision of household, health care, personal care, and veterinary products.",
          "enterpriseValue": 71569474000,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 34000,
          "sharesOutstanding": 801548028,
          "enterpriseToEbitda": 18.15562506341958,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 3.511405848297517,
          "operatingCashflowTTM": 4198000000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:20:09.319Z"
    },
    "results": [
      {
        "id": "cmnr12zcg02s0p658zwhctv81",
        "runId": "cmnr12zce02ryp658pt5qppnv",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CL\",\"currency\":\"USD\",\"current_price\":85.55,\"target_price_6m\":88.0,\"target_price_12m\":90.5,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"Defensive consumer staples leader with strong global brand portfolio\",\"TTM EPS declined 25% YoY, raising near-term earnings quality concerns\",\"Forward P/E of 20.3x implies significant EPS recovery priced in\",\"High debt-to-equity of 166% limits financial flexibility in downturn\",\"Dividend yield of ~2.9% offers modest income support at current levels\"],\"key_drivers\":[{\"driver\":\"Emerging markets volume recovery and pricing power\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Gross margin of 60% supports pricing resilience\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Sharp EPS YoY decline of -25% signals execution headwinds\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Flat organic revenue growth (~1.4% YoY) limits re-rating catalyst\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Strong FCF generation ($3.3B TTM) supports shareholder returns\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"High leverage (debt/equity 166%) elevates refinancing risk\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Low beta (0.24) provides portfolio defensiveness in volatile markets\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Pet nutrition (Hill's) segment provides premium growth vector\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FX headwinds from emerging market currency weakness\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"EPS recovery fails to materialize, compressing forward multiple\",\"Trade policy uncertainty raises input costs or disrupts supply chains\",\"Emerging market currency devaluation erodes translated earnings\",\"Private label share gains pressure oral care volumes in key markets\",\"Rising interest rates increase cost of servicing $9B debt load\"],\"assumptions\":{\"revenue_cagr_3y\":0.035,\"ebit_margin_target\":0.175,\"wacc\":0.078,\"terminal_multiple\":18.0},\"scenarios\":{\"bear\":{\"target_price\":76.0,\"prob\":0.2,\"notes\":\"EPS recovery stalls, multiple compresses to ~18x forward amid macro weakness.\"},\"base\":{\"target_price\":90.5,\"prob\":0.55,\"notes\":\"Gradual EPS recovery toward ~$4.20 forward, multiple holds near 21-22x.\"},\"bull\":{\"target_price\":100.0,\"prob\":0.25,\"notes\":\"Strong margin expansion and volume recovery drive EPS above $4.50, re-rating toward highs.\"}},\"method_notes\":\"Blended forward P/E and EV/EBITDA valuation. Forward EPS implied at ~$4.22 (from forward P/E 20.26). Applied 21-22x base-case P/E reflecting CL historical range for staples compounder. 12M target of $90.50 = ~5.8% upside, within HOLD band per rubric. High uncertainty from EPS decline and leverage temper conviction. Dividend yield adds ~2.9% to total return. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "EPS recovery fails to materialize, compressing forward multiple",
            "Trade policy uncertainty raises input costs or disrupts supply chains",
            "Emerging market currency devaluation erodes translated earnings",
            "Private label share gains pressure oral care volumes in key markets",
            "Rising interest rates increase cost of servicing $9B debt load"
          ],
          "ticker": "CL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Gradual EPS recovery toward ~$4.20 forward, multiple holds near 21-22x.",
              "target_price": 90.5
            },
            "bear": {
              "prob": 0.2,
              "notes": "EPS recovery stalls, multiple compresses to ~18x forward amid macro weakness.",
              "target_price": 76
            },
            "bull": {
              "prob": 0.25,
              "notes": "Strong margin expansion and volume recovery drive EPS above $4.50, re-rating toward highs.",
              "target_price": 100
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.078,
            "revenue_cagr_3y": 0.035,
            "terminal_multiple": 18,
            "ebit_margin_target": 0.175
          },
          "key_drivers": [
            {
              "driver": "Emerging markets volume recovery and pricing power",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Gross margin of 60% supports pricing resilience",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Sharp EPS YoY decline of -25% signals execution headwinds",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Flat organic revenue growth (~1.4% YoY) limits re-rating catalyst",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Strong FCF generation ($3.3B TTM) supports shareholder returns",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "High leverage (debt/equity 166%) elevates refinancing risk",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Low beta (0.24) provides portfolio defensiveness in volatile markets",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Pet nutrition (Hill's) segment provides premium growth vector",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "FX headwinds from emerging market currency weakness",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Blended forward P/E and EV/EBITDA valuation. Forward EPS implied at ~$4.22 (from forward P/E 20.26). Applied 21-22x base-case P/E reflecting CL historical range for staples compounder. 12M target of $90.50 = ~5.8% upside, within HOLD band per rubric. High uncertainty from EPS decline and leverage temper conviction. Dividend yield adds ~2.9% to total return. Not investment advice.",
          "current_price": 85.55,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Defensive consumer staples leader with strong global brand portfolio",
            "TTM EPS declined 25% YoY, raising near-term earnings quality concerns",
            "Forward P/E of 20.3x implies significant EPS recovery priced in",
            "High debt-to-equity of 166% limits financial flexibility in downturn",
            "Dividend yield of ~2.9% offers modest income support at current levels"
          ],
          "target_price_6m": 88,
          "target_price_12m": 90.5
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 39696,
        "createdAt": "2026-04-09T05:20:09.324Z",
        "usage": {
          "inputTokens": 3600,
          "outputTokens": 1865,
          "costUsd": 0.064625
        }
      },
      {
        "id": "cmnr12zcg02s3p658n94stbbe",
        "runId": "cmnr12zce02ryp658pt5qppnv",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Research Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"CL\",\n  \"currency\": \"USD\",\n  \"current_price\": 85.55,\n  \"target_price_6m\": 86.0,\n  \"target_price_12m\": 87.5,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.6,\n  \"thesis_bullets\": [\n    \"Stable consumer staples with strong brand equity.\",\n    \"Moderate revenue growth offset by high valuation.\",\n    \"Margin improvement from cost efficiencies expected.\",\n    \"High debt levels pose financial risk.\",\n    \"Dividend yield provides income support.\"\n  ],\n  \"key_drivers\": [\n    {\"driver\": \"Revenue growth\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"EBIT margin expansion\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n    {\"driver\": \"Debt management\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Currency fluctuations\", \"impact\": \"LOW\", \"direction\": \"NEG\"},\n    {\"driver\": \"Competitive pressure\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n    {\"driver\": \"Product innovation\", \"impact\": \"MED\", \"direction\": \"POS\"},\n    {\"driver\": \"Economic resilience\", \"impact\": \"LOW\", \"direction\": \"POS\"},\n    {\"driver\": \"Raw material costs\", \"impact\": \"MED\", \"direction\": \"NEG\"}\n  ],\n  \"risks\": [\"Slower-than-expected revenue growth\", \"Increased competition eroding market share\", \"Rising input costs squeezing margins\", \"High leverage increasing financial vulnerability\"],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.02,\n    \"ebit_margin_target\": 0.17,\n    \"wacc\": 0.07,\n    \"terminal_multiple\": 18\n  },\n  \"scenarios\": {\n    \"bear\": {\"target_price\": 80.0, \"prob\": 0.2, \"notes\": \"Margin compression and low growth dampen valuation.\"},\n    \"base\": {\"target_price\": 87.5, \"prob\": 0.6, \"notes\": \"Steady execution with modest improvements in margins.\"},\n    \"bull\": {\"target_price\": 95.0, \"prob\": 0.2, \"notes\": \"Strong margin expansion and market share gains boost earnings.\"}\n  },\n  \"method_notes\": \"Valuation using DCF with 2% revenue CAGR, 17% EBIT margin, 7% WACC, 18x terminal multiple. HOLD due to ~2.3% expected return and mixed growth signals. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Research Model",
          "risks": [
            "Slower-than-expected revenue growth",
            "Increased competition eroding market share",
            "Rising input costs squeezing margins",
            "High leverage increasing financial vulnerability"
          ],
          "ticker": "CL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady execution with modest improvements in margins.",
              "target_price": 87.5
            },
            "bear": {
              "prob": 0.2,
              "notes": "Margin compression and low growth dampen valuation.",
              "target_price": 80
            },
            "bull": {
              "prob": 0.2,
              "notes": "Strong margin expansion and market share gains boost earnings.",
              "target_price": 95
            }
          },
          "confidence": 0.6,
          "assumptions": {
            "wacc": 0.07,
            "revenue_cagr_3y": 0.02,
            "terminal_multiple": 18,
            "ebit_margin_target": 0.17
          },
          "key_drivers": [
            {
              "driver": "Revenue growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "EBIT margin expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Debt management",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Currency fluctuations",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Competitive pressure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Product innovation",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Economic resilience",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Raw material costs",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Valuation using DCF with 2% revenue CAGR, 17% EBIT margin, 7% WACC, 18x terminal multiple. HOLD due to ~2.3% expected return and mixed growth signals. Not investment advice.",
          "current_price": 85.55,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Stable consumer staples with strong brand equity.",
            "Moderate revenue growth offset by high valuation.",
            "Margin improvement from cost efficiencies expected.",
            "High debt levels pose financial risk.",
            "Dividend yield provides income support."
          ],
          "target_price_6m": 86,
          "target_price_12m": 87.5
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 342,
        "createdAt": "2026-04-09T05:20:09.324Z",
        "usage": {
          "inputTokens": 2110,
          "outputTokens": 3696,
          "costUsd": 0.002143
        }
      },
      {
        "id": "cmnr12zcg02s1p6583mis8nu4",
        "runId": "cmnr12zce02ryp658pt5qppnv",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"EquityResearch_DefensiveStaples_v1\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"CL\",\n  \"currency\": \"USD\",\n  \"current_price\": 85.55,\n  \"target_price_6m\": 86.50,\n  \"target_price_12m\": 88.00,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.70,\n  \"thesis_bullets\": [\n    \"Defensive consumer staples profile with a highly stable, low-beta (0.24) trading history.\",\n    \"Sluggish top-line growth (+1.4% YoY) limits significant upside potential at current valuation.\",\n    \"Gross margins remain strong at 60%, but operating margins face SG&A and input pressures.\",\n    \"Hill's Pet Nutrition provides a structural growth pocket, offsetting oral care maturity.\",\n    \"Current forward P/E of 20.3x appears fully valued given recent EPS contraction.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Pricing power\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Input cost inflation\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Hill's Pet Nutrition volume\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Emerging market FX headwinds\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Oral care market share\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Advertising & SG&A spend\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Supply chain efficiency\",\n      \"impact\": \"LOW\",\n      \"direction\": \"POS\"\n    }\n  ],\n  \"risks\": [\n    \"Prolonged inflation in agricultural and chemical inputs squeezing gross margins.\",\n    \"Consumer trade-down to private label oral care and pet food brands.\",\n    \"Adverse foreign exchange movements impacting emerging market revenue translation.\",\n    \"Higher interest rates increasing the burden of the $8.95B debt load.\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.025,\n    \"ebit_margin_target\": 0.18,\n    \"wacc\": 0.065,\n    \"terminal_multiple\": 18.0\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 75.00,\n      \"prob\": 0.30,\n      \"notes\": \"Inflation bites gross margins and consumers trade down, leading to volume declines.\"\n    },\n    \"base\": {\n      \"target_price\": 88.00,\n      \"prob\": 0.50,\n      \"notes\": \"Modest pricing power offsets volume softness, allowing margins to stabilize.\"\n    },\n    \"bull\": {\n      \"target_price\": 98.00,\n      \"prob\": 0.20,\n      \"notes\": \"Hill's Pet Nutrition accelerates and strong volume recovery drives operating leverage.\"\n    }\n  },\n  \"method_notes\": \"Valuation based on a blended 10-year DCF (WACC 6.5%, 2.5% terminal growth) and a 20x forward P/E multiple. The HOLD rating reflects limited upside (+2.8%) as sluggish volume growth and recent EPS contraction are fully priced in. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "EquityResearch_DefensiveStaples_v1",
          "risks": [
            "Prolonged inflation in agricultural and chemical inputs squeezing gross margins.",
            "Consumer trade-down to private label oral care and pet food brands.",
            "Adverse foreign exchange movements impacting emerging market revenue translation.",
            "Higher interest rates increasing the burden of the $8.95B debt load."
          ],
          "ticker": "CL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Modest pricing power offsets volume softness, allowing margins to stabilize.",
              "target_price": 88
            },
            "bear": {
              "prob": 0.3,
              "notes": "Inflation bites gross margins and consumers trade down, leading to volume declines.",
              "target_price": 75
            },
            "bull": {
              "prob": 0.2,
              "notes": "Hill's Pet Nutrition accelerates and strong volume recovery drives operating leverage.",
              "target_price": 98
            }
          },
          "confidence": 0.7,
          "assumptions": {
            "wacc": 0.065,
            "revenue_cagr_3y": 0.025,
            "terminal_multiple": 18,
            "ebit_margin_target": 0.18
          },
          "key_drivers": [
            {
              "driver": "Pricing power",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Input cost inflation",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Hill's Pet Nutrition volume",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Emerging market FX headwinds",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Oral care market share",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Advertising & SG&A spend",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Supply chain efficiency",
              "impact": "LOW",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on a blended 10-year DCF (WACC 6.5%, 2.5% terminal growth) and a 20x forward P/E multiple. The HOLD rating reflects limited upside (+2.8%) as sluggish volume growth and recent EPS contraction are fully priced in. Not investment advice.",
          "current_price": 85.55,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Defensive consumer staples profile with a highly stable, low-beta (0.24) trading history.",
            "Sluggish top-line growth (+1.4% YoY) limits significant upside potential at current valuation.",
            "Gross margins remain strong at 60%, but operating margins face SG&A and input pressures.",
            "Hill's Pet Nutrition provides a structural growth pocket, offsetting oral care maturity.",
            "Current forward P/E of 20.3x appears fully valued given recent EPS contraction."
          ],
          "target_price_6m": 86.5,
          "target_price_12m": 88
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "model": "gemini-3-pro-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 23593,
        "createdAt": "2026-04-09T05:20:09.324Z",
        "usage": {
          "inputTokens": 2458,
          "outputTokens": 901,
          "costUsd": 0.015728
        }
      },
      {
        "id": "cmnr12zcg02rzp6580218dgsm",
        "runId": "cmnr12zce02ryp658pt5qppnv",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"OpenAI o3\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"CL\",\"currency\":\"USD\",\"current_price\":85.55,\"target_price_6m\":82,\"target_price_12m\":83,\"recommendation\":\"HOLD\",\"confidence\":0.66,\"thesis_bullets\":[\"Oral-care leadership supports resilient pricing and steady category share.\",\"Free-cash-flow generation underpins dividends, buybacks, and brand investment.\",\"Recent EPS decline and muted revenue growth argue against aggressive multiple expansion.\",\"Current valuation remains premium for a low-single-digit growth staples business.\",\"Defensive qualities limit downside, but upside appears capped near fair value.\"],\"key_drivers\":[{\"driver\":\"Pricing and premium mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Emerging-market volume recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margin normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"FX translation headwinds\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Hill's pet nutrition growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Dividend and buyback support\",\"impact\":\"LOW\",\"direction\":\"POS\"},{\"driver\":\"Private-label competition\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"FX swings and emerging-market volatility\",\"Commodity cost inflation reaccelerates\",\"Private-label or retailer bargaining pressure\",\"Premium multiple compresses on slower growth\",\"Regulatory or tax changes in key markets\"],\"assumptions\":{\"revenue_cagr_3y\":3,\"ebit_margin_target\":17.5,\"wacc\":7,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":72,\"prob\":0.25,\"notes\":\"FX and volume weakness drive a de-rating despite defensive demand.\"},\"base\":{\"target_price\":83,\"prob\":0.55,\"notes\":\"Low-single-digit sales growth and modest margin expansion keep shares near fair value.\"},\"bull\":{\"target_price\":92,\"prob\":0.2,\"notes\":\"Pricing sticks, margins recover, and investors sustain the staple premium.\"}},\"method_notes\":\"Base case uses snapshot fundamentals with a normalized cash-flow and EV/EBIT cross-check; no sell-side targets used. Snapshot quote fields were not overridden. Trailing and forward multiples diverge, so confidence is moderate. HOLD reflects near-fair value with modest downside risk. not investment advice\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "OpenAI o3",
          "risks": [
            "FX swings and emerging-market volatility",
            "Commodity cost inflation reaccelerates",
            "Private-label or retailer bargaining pressure",
            "Premium multiple compresses on slower growth",
            "Regulatory or tax changes in key markets"
          ],
          "ticker": "CL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Low-single-digit sales growth and modest margin expansion keep shares near fair value.",
              "target_price": 83
            },
            "bear": {
              "prob": 0.25,
              "notes": "FX and volume weakness drive a de-rating despite defensive demand.",
              "target_price": 72
            },
            "bull": {
              "prob": 0.2,
              "notes": "Pricing sticks, margins recover, and investors sustain the staple premium.",
              "target_price": 92
            }
          },
          "confidence": 0.66,
          "assumptions": {
            "wacc": 7,
            "revenue_cagr_3y": 3,
            "terminal_multiple": 18,
            "ebit_margin_target": 17.5
          },
          "key_drivers": [
            {
              "driver": "Pricing and premium mix",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Emerging-market volume recovery",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Gross margin normalization",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "FX translation headwinds",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Hill's pet nutrition growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Premium valuation multiple",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Dividend and buyback support",
              "impact": "LOW",
              "direction": "POS"
            },
            {
              "driver": "Private-label competition",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Base case uses snapshot fundamentals with a normalized cash-flow and EV/EBIT cross-check; no sell-side targets used. Snapshot quote fields were not overridden. Trailing and forward multiples diverge, so confidence is moderate. HOLD reflects near-fair value with modest downside risk. not investment advice",
          "current_price": 85.55,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Oral-care leadership supports resilient pricing and steady category share.",
            "Free-cash-flow generation underpins dividends, buybacks, and brand investment.",
            "Recent EPS decline and muted revenue growth argue against aggressive multiple expansion.",
            "Current valuation remains premium for a low-single-digit growth staples business.",
            "Defensive qualities limit downside, but upside appears capped near fair value."
          ],
          "target_price_6m": 82,
          "target_price_12m": 83
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_019b89405a0a735d0069d7572ddf548193b7431ac7541901db",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 47173,
        "createdAt": "2026-04-09T05:20:09.324Z",
        "usage": {
          "inputTokens": 2375,
          "outputTokens": 2699,
          "costUsd": 0.041942
        }
      },
      {
        "id": "cmnr12zcg02s2p658edzc64lq",
        "runId": "cmnr12zce02ryp658pt5qppnv",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Fundamental Valuation Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"CL\",\n  \"currency\": \"USD\",\n  \"current_price\": 85.55,\n  \"target_price_6m\": 90,\n  \"target_price_12m\": 95,\n  \"recommendation\": \"BUY\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Defensive business model with strong brands in daily essentials.\",\n    \"Forward valuation attractive relative to cash flow stability.\",\n    \"Growth in emerging markets to accelerate revenue CAGR.\",\n    \"Cost inflation and competition may pressure near-term margins.\",\n    \"Solid FCF supports dividends and buybacks over long term.\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Strong oral care brand moat\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Modest organic revenue growth\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Input cost pressures\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Emerging markets expansion\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"High free cash flow yield\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Elevated debt levels\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Product innovation pipeline\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competition from P&G\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Rising raw material costs\",\n    \"Slower volume growth in key markets\",\n    \"Adverse FX movements\",\n    \"Intense competitive pressure\",\n    \"Regulatory changes on ingredients\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 3.5,\n    \"ebit_margin_target\": 17.5,\n    \"wacc\": 7.5,\n    \"terminal_multiple\": 21\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 78,\n      \"prob\": 0.25,\n      \"notes\": \"Margin compression from higher costs and weak volumes.\"\n    },\n    \"base\": {\n      \"target_price\": 95,\n      \"prob\": 0.5,\n      \"notes\": \"Consistent execution with mid-single digit growth.\"\n    },\n    \"bull\": {\n      \"target_price\": 112,\n      \"prob\": 0.25,\n      \"notes\": \"Strong EM growth and margin expansion from efficiencies.\"\n    }\n  },\n  \"method_notes\": \"DCF using assumed revenue CAGR, EBIT margin, WACC and terminal multiple. 12M base implies ~11% upside plus yield. not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Fundamental Valuation Model",
          "risks": [
            "Rising raw material costs",
            "Slower volume growth in key markets",
            "Adverse FX movements",
            "Intense competitive pressure",
            "Regulatory changes on ingredients"
          ],
          "ticker": "CL",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Consistent execution with mid-single digit growth.",
              "target_price": 95
            },
            "bear": {
              "prob": 0.25,
              "notes": "Margin compression from higher costs and weak volumes.",
              "target_price": 78
            },
            "bull": {
              "prob": 0.25,
              "notes": "Strong EM growth and margin expansion from efficiencies.",
              "target_price": 112
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 7.5,
            "revenue_cagr_3y": 3.5,
            "terminal_multiple": 21,
            "ebit_margin_target": 17.5
          },
          "key_drivers": [
            {
              "driver": "Strong oral care brand moat",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Modest organic revenue growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Input cost pressures",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Emerging markets expansion",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "High free cash flow yield",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Elevated debt levels",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Product innovation pipeline",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competition from P&G",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF using assumed revenue CAGR, EBIT margin, WACC and terminal multiple. 12M base implies ~11% upside plus yield. not investment advice.",
          "current_price": 85.55,
          "recommendation": "BUY",
          "thesis_bullets": [
            "Defensive business model with strong brands in daily essentials.",
            "Forward valuation attractive relative to cash flow stability.",
            "Growth in emerging markets to accelerate revenue CAGR.",
            "Cost inflation and competition may pressure near-term margins.",
            "Solid FCF supports dividends and buybacks over long term."
          ],
          "target_price_6m": 90,
          "target_price_12m": 95
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "aaa5acff-d831-9026-b07b-c6eb9d1b19be",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 23830,
        "createdAt": "2026-04-09T05:20:09.324Z",
        "usage": {
          "inputTokens": 2717,
          "outputTokens": 4041,
          "costUsd": 0.068766
        }
      }
    ]
  }
}